TP53 and cancer: Our own unpublished data from the Meirav high-risk clinic show that 4/965 (0.4%) of BRCA1 or BRCA2 PSV carriers also have a PSV in MSH2, MSH6, or TP53. Weitzel and colleagues [9] reported that 47/55,803 (0.084%) cases genotyped for a 25-gene panel had a DH PSV in high-penetrance cancer genes.